PriceTargets.com logo

Bristol-Myers Squibb - BMY Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $54.07
  • Forecasted Upside: -6.58%
  • Number of Analysts: 20
  • Breakdown:
  • 2 Sell Ratings
  • 14 Hold Ratings
  • 2 Buy Ratings
  • 2 Strong Buy Ratings
$57.88 As of 11/20/2024 01:00 AM ET
▼ -0.35 (-0.60%)

This chart shows the closing price for BMY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bristol-Myers Squibb Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMY

Analyst Price Target is $54.07
▼ -6.58% Downside Potential
This price target is based on 20 analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is $54.07, with a high forecast of $73.00 and a low forecast of $39.00. The average price target represents a -6.58% upside from the last price of $57.88.

This chart shows the closing price for BMY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 20 investment analysts is to hold stock in Bristol-Myers Squibb. This rating changed within the last month from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 2 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 13 hold ratings
  • 1 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 15 hold ratings
  • 1 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 15 hold ratings
  • 1 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 12 hold ratings
  • 2 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
10/22/2024
  • 2 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 2 strong buy ratings
  • 2 buy ratings
  • 14 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Wolfe ResearchInitiated CoveragePeer Perform
11/13/2024Daiwa AmericaUpgradeHold ➝ Strong-Buy
11/13/2024Daiwa Capital MarketsUpgradeNeutral ➝ Outperform
11/12/2024Leerink PartnrsUpgradeHold ➝ Strong-Buy
11/12/2024CitigroupBoost TargetNeutral ➝ Neutral$55.00 ➝ $60.00
11/12/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$57.00 ➝ $61.00
11/12/2024Morgan StanleyBoost TargetUnderweight ➝ Underweight$36.00 ➝ $39.00
11/12/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$55.00 ➝ $73.00
11/1/2024BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$53.00 ➝ $57.00
10/25/2024CitigroupDowngradeBuy ➝ Neutral$75.00 ➝ $55.00
10/18/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$50.00 ➝ $50.00
10/17/2024Sanford C. BernsteinInitiated CoverageMarket Perform$56.00
10/9/2024UBS GroupBoost TargetNeutral ➝ Neutral$50.00 ➝ $54.00
10/7/2024BarclaysBoost TargetUnderweight ➝ Underweight$42.00 ➝ $43.00
10/7/2024TD CowenBoost TargetHold ➝ Hold$53.00 ➝ $59.00
9/23/2024BMO Capital MarketsReiterated RatingMarket Perform ➝ Market Perform$48.00 ➝ $48.00
9/16/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$50.00 ➝ $50.00
8/28/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$49.00 ➝ $51.00
8/22/2024BarclaysBoost TargetUnderweight ➝ Underweight$41.00 ➝ $42.00
8/12/2024TD CowenBoost TargetHold ➝ Hold$45.00 ➝ $53.00
7/29/2024BarclaysDowngradeOverweight ➝ Equal Weight$41.00 ➝ $41.00
7/23/2024Deutsche Bank AktiengesellschaftLower TargetHold ➝ Hold$53.00 ➝ $45.00
7/22/2024Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$45.00 ➝ $45.00
7/10/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$43.00 ➝ $41.00
4/26/2024BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$55.00 ➝ $48.00
4/26/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$51.00 ➝ $43.00
4/18/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$51.00 ➝ $52.00
4/1/2024William BlairReiterated RatingMarket Perform
3/11/2024Societe GeneraleDowngradeBuy ➝ Hold
2/6/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$58.00 ➝ $51.00
2/6/2024Redburn AtlanticDowngradeBuy ➝ Neutral$77.00 ➝ $54.00
1/3/2024Bank of AmericaDowngradeBuy ➝ Neutral$68.00 ➝ $60.00
12/27/2023Bank of AmericaLower TargetBuy ➝ Buy$72.00 ➝ $68.00
11/15/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$68.00 ➝ $55.00
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$55.00
11/2/2023Daiwa Capital MarketsDowngradeOutperform ➝ Neutral$68.00 ➝ $54.00
10/30/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$81.00 ➝ $69.00
10/27/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$56.00 ➝ $50.00
10/27/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$60.00 ➝ $51.00
10/27/2023BMO Capital MarketsDowngradeOutperform ➝ Market Perform$60.00
10/27/2023William BlairDowngradeOutperform ➝ Market Perform
10/27/2023HSBCUpgradeReduce ➝ Hold$55.00 ➝ $53.00
10/20/2023UBS GroupReiterated RatingNeutral ➝ Neutral$70.00 ➝ $60.00
10/11/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$57.00 ➝ $56.00
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
10/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$84.00
10/2/2023BarclaysLower Target$62.00 ➝ $60.00
9/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$75.00
9/15/2023TD CowenLower TargetMarket Perform ➝ Market Perform$80.00 ➝ $66.00
9/15/2023Truist FinancialReiterated RatingBuy ➝ Buy$84.00
7/28/2023Wells Fargo & CompanyLower TargetEqual Weight$78.00 ➝ $65.00
7/28/2023BMO Capital MarketsLower TargetOutperform$87.00 ➝ $79.00
7/28/2023Bank of AmericaLower TargetBuy$85.00 ➝ $80.00
7/28/2023Atlantic SecuritiesLower TargetOverweight$90.00 ➝ $85.00
7/28/2023BarclaysLower TargetEqual Weight$64.00 ➝ $62.00
7/19/2023Morgan StanleyReiterated RatingUnderweight ➝ Underweight$59.00 ➝ $59.00
7/19/2023Cantor FitzgeraldLower TargetOverweight$88.00 ➝ $85.00
7/18/2023BMO Capital MarketsLower Target$92.00 ➝ $87.00
7/14/2023HSBCInitiated CoverageReduce$56.00
7/12/2023Credit Suisse GroupLower Target$72.00 ➝ $66.00
7/11/2023BarclaysLower Target$65.00 ➝ $64.00
7/10/2023Leerink PartnersReiterated RatingMarket Perform
7/10/2023SVB SecuritiesInitiated CoverageMarket Perform$66.00
6/28/2023Daiwa Capital MarketsInitiated CoverageOutperform$70.00
5/1/2023BarclaysLower Target$66.00 ➝ $65.00
4/28/202351jobReiterated RatingMaintains
4/28/2023Credit Suisse GroupLower Target$78.00 ➝ $72.00
4/21/2023Bank of AmericaBoost TargetBuy$82.00 ➝ $85.00
3/6/2023Jefferies Financial GroupInitiated CoverageHold$62.00
2/3/2023Morgan StanleyBoost TargetUnderweight$60.00 ➝ $62.00
2/3/2023Atlantic SecuritiesBoost TargetOverweight$88.00 ➝ $90.00
1/17/2023Cantor FitzgeraldInitiated CoverageOverweight$95.00
1/3/2023Wells Fargo & CompanyBoost TargetEqual Weight$70.00 ➝ $78.00
11/17/2022Credit Suisse GroupInitiated CoverageNeutral$78.00
11/10/2022Atlantic SecuritiesBoost TargetOverweight$85.00 ➝ $88.00
10/27/2022Morgan StanleyLower TargetUnderweight$61.00 ➝ $60.00
10/27/2022Atlantic SecuritiesLower TargetOverweight$87.00 ➝ $85.00
10/12/2022BarclaysLower TargetEqual Weight$69.00 ➝ $66.00
10/10/2022GuggenheimDowngradeBuy ➝ Neutral
9/27/2022The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$85.00
9/14/2022Berenberg BankDowngradeBuy ➝ Hold$82.00 ➝ $76.00
9/12/2022BMO Capital MarketsBoost TargetOutperform$92.00 ➝ $94.00
9/12/2022Atlantic SecuritiesBoost TargetOverweight$83.00 ➝ $87.00
7/28/2022Atlantic SecuritiesBoost TargetOverweight$82.00 ➝ $83.00
7/28/2022JPMorgan Chase & Co.Boost Target$80.00 ➝ $85.00
7/27/2022UBS GroupBoost TargetOutperform$73.00
6/6/2022Bank of AmericaBoost TargetBuy ➝ Buy$78.00 ➝ $80.00
6/3/2022CitigroupReiterated RatingBuy$90.00
6/3/2022Raymond JamesDowngradeOutperform ➝ Market Perform
5/26/2022CitigroupBoost TargetBuy$75.00 ➝ $90.00
5/17/2022Wells Fargo & CompanyBoost TargetEqual Weight$65.00 ➝ $70.00
5/2/2022Truist FinancialBoost Target$76.00 ➝ $81.00
5/2/2022BMO Capital MarketsBoost Target$87.00 ➝ $92.00
5/2/2022GuggenheimBoost Target$72.00 ➝ $80.00
5/2/2022BarclaysBoost Target$66.00 ➝ $68.00
4/6/2022Morgan StanleyLower TargetEqual Weight ➝ Underweight$66.00 ➝ $64.00
3/30/2022BMO Capital MarketsBoost TargetOutperform$74.00 ➝ $81.00
3/2/2022Wells Fargo & CompanyBoost TargetEqual Weight$60.00 ➝ $65.00
12/17/2021The Goldman Sachs GroupInitiated CoverageBuy$72.00
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$58.00
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$72.00
11/1/2021ArgusDowngradeBuy ➝ Hold$49.00
10/28/2021BarclaysLower TargetEqual Weight$68.00 ➝ $66.00
10/12/2021Morgan StanleyLower TargetEqual Weight$71.00 ➝ $66.00
10/11/2021Berenberg BankLower TargetBuy$75.00 ➝ $71.00
10/8/2021BarclaysLower TargetEqual Weight$71.00 ➝ $68.00
7/29/2021Morgan StanleyBoost TargetEqual Weight$62.00 ➝ $71.00
7/28/2021Truist FinancialInitiated CoverageBuy$74.00
7/28/2021Bank of AmericaReiterated RatingBuy
5/6/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$62.00
4/30/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$70.00 ➝ $62.00
4/13/2021Truist FinancialUpgradeHold ➝ Buy
12/15/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
11/30/2020Smith Barney CitigroupBoost Target$73.00 ➝ $77.00
11/16/2020Societe GeneraleUpgradeHold ➝ Buy$76.00
11/10/2020Sanford C. BernsteinReiterated RatingMarket Perform$72.00
11/6/2020GabelliDowngradeBuy ➝ Hold
10/23/2020Truist FinancialInitiated CoverageHold$65.00
10/19/2020GuggenheimUpgradeNeutral ➝ Buy$70.00
10/16/2020JPMorgan Chase & Co.Boost TargetOverweight$74.00 ➝ $78.00
9/29/2020Berenberg BankInitiated CoverageBuy$73.00
9/25/2020Raymond JamesReiterated RatingBuy
9/22/2020Raymond JamesBoost TargetOutperform$75.00 ➝ $78.00
8/12/2020Morgan StanleyBoost TargetOverweight$64.00 ➝ $66.00
7/28/2020Raymond JamesInitiated CoverageOutperform$75.00
7/26/2020CfraReiterated RatingBuy$70.00
6/2/2020Cantor FitzgeraldBoost Target$68.00 ➝ $88.00
6/1/2020William BlairReiterated RatingBuy
5/15/2020Bank of AmericaReiterated RatingBuy$80.00
5/15/2020William BlairReiterated RatingBuy
5/7/2020CfraBoost TargetBuy$69.00 ➝ $70.00
4/2/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$64.00
4/1/2020Bank of AmericaReiterated RatingBuy$75.00
3/23/2020Societe GeneraleDowngradeBuy ➝ Hold$50.00
2/27/2020BarclaysInitiated CoverageEqual Weight$69.00
2/14/2020William BlairReiterated RatingBuy
1/6/2020CitigroupUpgradeNeutral ➝ Buy$73.00
12/13/2019William BlairReiterated RatingBuy
12/13/2019ArgusUpgradeHold ➝ Buy$80.00
11/27/2019GabelliInitiated CoverageBuy
11/25/2019MizuhoInitiated CoverageBuy
11/22/2019Morgan StanleyInitiated CoverageEqual Weight$60.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 65 very positive mentions
  • 47 positive mentions
  • 10 negative mentions
  • 3 very negative mentions
Mentions as of
4/24/2024
  • 60 very positive mentions
  • 65 positive mentions
  • 28 negative mentions
  • 4 very negative mentions
Mentions as of
5/24/2024
  • 51 very positive mentions
  • 38 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 45 very positive mentions
  • 32 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 57 very positive mentions
  • 54 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 46 very positive mentions
  • 30 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 52 very positive mentions
  • 38 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
10/21/2024
  • 109 very positive mentions
  • 70 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 109 very positive mentions
  • 70 positive mentions
  • 8 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Bristol-Myers Squibb logo
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $57.88
Low: $57.67
High: $58.83

50 Day Range

MA: $53.26
Low: $48.25
High: $59.82

52 Week Range

Now: $57.88
Low: $39.35
High: $61.08

Volume

10,594,627 shs

Average Volume

14,426,227 shs

Market Capitalization

$117.39 billion

P/E Ratio

N/A

Dividend Yield

4.23%

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Bristol-Myers Squibb?

The following Wall Street analysts have issued stock ratings on Bristol-Myers Squibb in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Daiwa America, Daiwa Capital Markets, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Leerink Partners, Leerink Partnrs, Morgan Stanley, Redburn Atlantic, Sanford C. Bernstein, Societe Generale, StockNews.com, TD Cowen, UBS Group AG, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for BMY.

What is the current price target for Bristol-Myers Squibb?

0 Wall Street analysts have set twelve-month price targets for Bristol-Myers Squibb in the last year. Their average twelve-month price target is $54.07, suggesting a possible downside of 6.6%. Leerink Partners has the highest price target set, predicting BMY will reach $73.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $39.00 for Bristol-Myers Squibb in the next year.
View the latest price targets for BMY.

What is the current consensus analyst rating for Bristol-Myers Squibb?

Bristol-Myers Squibb currently has 2 sell ratings, 14 hold ratings, 2 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BMY, but not buy more shares or sell existing shares.
View the latest ratings for BMY.

What other companies compete with Bristol-Myers Squibb?

Other companies that are similar to Bristol-Myers Squibb include Johnson & Johnson, AbbVie, Merck & Co., Inc., Pfizer and Zoetis. Learn More about companies similar to Bristol-Myers Squibb.

How do I contact Bristol-Myers Squibb's investor relations team?

Bristol-Myers Squibb's physical mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company's listed phone number is (212) 546-4000 and its investor relations email address is [email protected]. The official website for Bristol-Myers Squibb is www.bms.com. Learn More about contacing Bristol-Myers Squibb investor relations.